P. Garzone

发表

P. Garzone, Tianjun Wang, 2020, Acupuncture for Brain.

Model-Based Characterization of the Pharmacokinetics, Target Engagement Biomarkers, and Immunomodulatory Activity of PF-06342674, a Humanized mAb Against IL-7 Receptor-α, in Adults with Type 1 Diabetes

Samantha L. Bucktrout, P. Garzone, T. Joh, 2020, The AAPS Journal.

Pharmacokinetic and pharmacodynamic considerations in the development of biotechnology products and large molecules

Yow-Ming C Wang, P. Garzone, P. D. Garzone, 2022, Atkinson's Principles of Clinical Pharmacology.

Chapter 34 – Pharmacokinetic and Pharmacodynamic Considerations in the Development of Biotechnology Products and Large Molecules

P. Garzone, 2012 .

Pharmacokinetic and Pharmacodynamic Considerations in the Development of Biotechnology Products and Large Molecules

P. Garzone, Pamela D. Garzone, 2007 .

Enhancement of the Efficacy of An Antagonist of an Extracellular Receptor by Attachment to the Surface of a Biocompatible Carrier

Charles A. Wartchow, Zhimin Shen, P. Garzone, 2004, Pharmaceutical Research.

Steady‐state moxalactam kinetics: Comparisons with other cephalosporins

V. Yu, P. Garzone, W. Diven, 1981, Clinical pharmacology and therapeutics.

Single and multiple ascending-dose study of glucagon-receptor antagonist RN909 in type 2 diabetes: a phase 1, randomized, double-blind, placebo-controlled trial

B. Gumbiner, P. Garzone, T. Joh, 2018, Endocrine.

Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: Results of the Phase 1 program

M. Bigal, P. Garzone, J. P. Huggins, 2014, Cephalalgia : an international journal of headache.

Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high‐dose statin

C. Baum, B. Gumbiner, S. Fazio, 2018, Cardiovascular therapeutics.

The effects of single‐ and multiple‐dose administration of bococizumab (RN316/PF‐04950615), a humanized IgG2&Dgr;a monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies

C. Baum, J. Pons, B. Gumbiner, 2018, Cardiovascular therapeutics.

Recombinant human factor IX: replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B.

R. Schaub, P. Garzone, M. Read, 1996, Blood.

Pharmacokinetic Profile of Orally Administered Scyllo‐Inositol (Elnd005) in Plasma, Cerebrospinal Fluid and Brain, and Corresponding Effect on Amyloid‐Beta in Healthy Subjects

J. Cedarbaum, L. Ereshefsky, P. Garzone, 2013, Clinical pharmacology in drug development.

An investigational therapy for geographic atrophy in age-related macular degeneration

C. B. Rickman, P. Garzone, John C. Lin, 2014 .

Phase I, Masked, Placebo-Controlled, Single and Multiple Ascending Intravenous Dose Studies Evaluating Systemic and Ocular Safety, Tolerability, and Visual Acuity Effects of RN6G (PF-04382923) in Subjects with Dry, Age-Related Macular Degeneration (ARMD)

K. Liao, P. Garzone, John C. Lin, 2013 .

Oral amyloid anti-aggregating agent ELND005 is measurable in CSF and brain of healthy adult men

J. Cedarbaum, L. Ereshefsky, P. Garzone, 2009, Alzheimer's & Dementia.

Clinical evaluation of recombinant factor IX.

P. Garzone, M. Ragni, G. White, 1998, Seminars in hematology.

In Search of Physiologically Based Distribution Volume Estimates for Macromolecules

A. Atkinson, P. Garzone, A. Atkinson, 2012, Clinical pharmacology and therapeutics.

Preclinical studies of recombinant factor IX.

R. Schaub, P. Garzone, K. Brinkhous, 1998, Seminars in hematology.

Third-Generation and Investigational Cephalosporins: II. Microbiologic Review and Clinical Summaries

V. Yu, P. Garzone, J. Lyon, 1983, Drug intelligence & clinical pharmacy.

Third-Generation and Investigational Cephalosporins: I. Structure-Activity Relationships and Pharmacokinetic Review

V. Yu, P. Garzone, J. Lyon, 1983, Drug intelligence & clinical pharmacy.

Molecular Characterization of Familial Hypercholesterolemia in a North American Cohort.

Danielle E. Dettling, M. Sirota, A. Garg, 2019, Journal of the Endocrine Society.

Phase I study of CCW702, a bispecific small molecule-antibody conjugate targeting PSMA and CD3 in patients with metastatic castration-resistant prostate cancer (mCRPC).

E. Heath, R. Dreicer, M. Trikha, 2021 .

Pharmacokinetics of the Newer Benzodiazepines

P. Kroboth, P. Garzone, 1989, Clinical pharmacokinetics.

Pain perception and serum beta-endorphin in trauma patients.

T. Rudy, B. Kramer, L. Bernstein, 1995, Psychosomatics.

Increasing Serum Half-life and Extending Cholesterol Lowering in Vivo by Engineering Antibody with pH-sensitive Binding to PCSK9*

Rachel M. Devay, J. Chaparro-Riggers, A. Rajpal, 2012, The Journal of Biological Chemistry.

Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.

M. Atkins, J. Ritz, M. Lotze, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Immunomodulatory activity of humanized anti-IL-7R monoclonal antibody RN168 in subjects with type 1 diabetes.

J. McGill, S. Potluri, B. Bode, 2019, JCI insight.

First in human (FIH) study of an OX40 agonist monoclonal antibody (mAb) PF-04518600 (PF-8600) in adult patients (pts) with select advanced solid tumors: Preliminary safety and pharmacokinetic (PK)/pharmacodynamic results.

D. Nuyten, A. El-Khoueiry, O. Hamid, 2016 .

Comparison of the spectrum of cognitive effects of alprazolam and adinazolam after single doses in healthy subjects

H. Weingartner, K. Sirocco, P. Garzone, 1995, Psychopharmacology.

Poly-(L)-glutamic acid-paclitaxel (CT-2103) [XYOTAX], a biodegradable polymeric drug conjugate: characterization, preclinical pharmacology, and preliminary clinical data.

S. Shaffer, J. Singer, Anil Kumar, 2003, Advances in experimental medicine and biology.

Clinical pharmacology assessment of PF-06647020 (PF-7020), an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in adult patients (pts) with advanced solid tumors.

D. Xuan, M. Maitland, A. Tolcher, 2018 .

A Mechanism‐Based Pharmacokinetic/Pharmacodynamic Model for Bococizumab, a Humanized Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, and Its Application in Early Clinical Development

K. Liao, B. Gumbiner, P. Garzone, 2017, Journal of clinical pharmacology.

Abstract 13322: The Effects of Single Dose Administration of RN316 (PF-04950615), a Humanized IgG2a Monoclonal Antibody Binding Proprotein Convertase Subtilisin Kexin Type 9, in Hypercholesterolemic Subjects Treated with and without Atorvastatin

C. Baum, J. Pons, B. Gumbiner, 2012 .

Abstract 13524: The Effects of Multiple Dose Administration of RN316 (PF-04950615), a Humanized IgG2a Monoclonal Antibody Binding Proprotein Convertase Subtilisin Kexin Type 9, in Hypercholesterolemic Subjects

C. Baum, J. Pons, B. Gumbiner, 2012 .

Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition with Bococizumab on Lipoprotein Particles in Hypercholesterolemic Subjects.

B. Gumbiner, P. Garzone, T. Joh, 2017, Clinical therapeutics.

Pharmacokinetic Profile of Orally Administered Scyllo‐Inositol (Elnd005) in Plasma, Cerebrospinal Fluid and Brain, and Corresponding Effect on Amyloid‐Beta in Healthy Subjects

J. Cedarbaum, L. Ereshefsky, P. Garzone, 2013, Clinical pharmacology in drug development.

Chapter 34 – Pharmacokinetic and Pharmacodynamic Considerations in the Development of Biotechnology Products and Large Molecules

P. Garzone, 2012 .